Skip to Content

Primaquine Pregnancy and Breastfeeding Warnings

Primaquine Pregnancy Warnings

AU: Use of antimalarials to treat malaria is considered acceptable; the benefits to the mother and fetus outweigh the risk to the fetus. US: This drug should not be used during pregnancy unless the benefit outweighs the risk to the fetus; safety has not been established during pregnancy. AU TGA pregnancy category: D US FDA pregnancy category: Not formally assigned to a pregnancy category.

Animal studies have not been reported. There are no controlled data in human pregnancy; no cases of congenital defects reported. This drug has been shown to cross the placenta. There is a theoretical risk of hemolytic anemia in a glucose-6-phosphate dehydrogenase (G6PD)-deficient fetus. Some experts recommend that this drug be avoided in pregnancy because the G6PD status of the fetus cannot be determined. AU TGA pregnancy category D: Drugs which have caused, are suspected to have caused or may be expected to cause, an increased incidence of human fetal malformations or irreversible damage. These drugs may also have adverse pharmacological effects. Accompanying texts should be consulted for further details.

See references

Primaquine Breastfeeding Warnings

In a trial, lactating mothers at risk for recurrent vivax malaria received 0.5 mg/kg/day. Preliminary results showed no drug-related side effects in their nursing infants (aged at least 28 days). Low but measurable levels of this drug were found in breast milk and infant plasma. The very small amounts of antimalarial drugs transferred in breast milk are insufficient to provide adequate protection against malaria. If prophylaxis is required, infants should receive recommended doses of antimalarial drugs. Current guidelines should be consulted for additional information.

This drug should not be used unless the breastfeeding mother and infant have normal glucose-6-phosphate dehydrogenase (G6PD) levels. Excreted into human milk: Yes (low levels) Comments: -If therapy is required, the mother and infant should be tested for G6PD deficiency before this drug is administered to a breastfeeding woman. -The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. Cerner Multum, Inc. "Australian Product Information." O 0
  2. Briggs GG, Freeman RK, Yaffe SJ.. "Drugs in Pregnancy and Lactation. 5th ed." Baltimore, MD: Williams & Wilkins (1998):
  3. Freedman DO "Clinical practice. Malaria prevention in short-term travelers." N Engl J Med 359 (2008): 603-12
  4. World Health Organization "Guidelines for the Treatment of Malaria – Third edition. Available from: URL:" (2015):
  5. Baird JK, Fryauff DJ, Hoffman SL "Primaquine for prevention of malaria in travelers." Clin Infect Dis 37 (2003): 1659-67
  6. "Product Information. Primaquine (primaquine)." Sanofi Winthrop Pharmaceuticals, New York, NY.
  7. Arguin PM, Tan KR "Infectious Diseases Related to Travel. Malaria. Available from: URL:" ([2015, Jul 10]):

References for breastfeeding information

  1. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL:" ([cited 2013 -]):
  2. "Product Information. Primaquine (primaquine)." Sanofi Winthrop Pharmaceuticals, New York, NY.
  3. Cerner Multum, Inc. "Australian Product Information." O 0
  4. Gilder ME, Tarning J, Lindeganullrdh NH, et al "A study of the pharmacokinetics of primaquine in lactating women and breastfed infants for the radical treatment of uncomplicated maternal plasmodium vivax." Am J Trop Med Hyg 91 (2014): 587
  5. Arguin PM, Tan KR "Infectious Diseases Related to Travel. Malaria. Available from: URL:" ([2015, Jul 10]):
  6. World Health Organization "Guidelines for the Treatment of Malaria – Third edition. Available from: URL:" (2015):

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.